Hypertension Monitoring in Glioma Patients Treated With Bevacizumab

NCT01046279•University of Zurich

Summary

Prospective casecontrol study in glioma patients undergoing treatment with bevacizumab (Avastin). At present there are no data on the correlation between occurrence of arterial hypertension and clinical outcome in patients with glioma or anaplastic astrocytoma. We will investigate whether glioma patients developing hypertension under bevacizumab treatment have a better outcome in terms of progression free survival, response rate and overall survival than equally treated patients remaining normotensive. Moreover, we will describe the dynamics of change in blood pressure after administration of bevacizumab in those patients developing hypertension. * Trial with medicinal product

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Locations (1)

University Hospital Zurich, Internal Medicine

Zurich, Canton of Zurich, Switzerland

Key Dates

Start Date

January 1, 2010

Primary Completion Date

August 1, 2012

Completion Date

August 1, 2012

Last Updated

June 13, 2013

Enrollment

ACTUAL participants

Conditions

Glioma Patients

Interventions

Bevacizumab

DRUG

CTCs for High Grade Glioma

NCT02558335

Stage III and IV Glioma Patients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions